A Dozen Executives Filed Stock Sales in a Single Day, Spanning Healthcare to Chips

A wave of insider stock sales hit the wires covering the latest session, spanning companies with little in common beyond the timing of their filings. Astera Labs director Stefan Dyckerhoff sold $4.7 million in shares, the largest single disclosure in the group. Waystar CEO Matthew Hawkins sold $2.16 million, Vaxcyte's EVP and COO Jim Wassil sold $1.56 million and its SVP Elvia Cowan sold $1.6 million separately, and Neptune Insurance Holdings president Matthew Duffy sold $1.12 million. Smaller filings came from Castle Biosciences CEO Derek Maetzold ($515,000), Twist Bioscience CEO Emily Leproust ($919,373), Capital One general counsel Matthew Cooper ($686,770), Intapp CEO John Hall ($109,500), Finance of America CIO Jeremy Prahm ($79,202), Progress Software's chief legal officer ($46,065) and Blend Labs head Nima Ghamsari, who sold just $24,660. Taken individually, none of these filings is unusual — executives routinely sell shares for diversification, tax planning or pre-scheduled trading plans, and the filings do not disclose whether these were 10b5-1 sales set up in advance. What is unresolved is whether the clustering across so many unrelated sectors in one reporting window reflects anything beyond coincidence of filing deadlines; the wire reports do not indicate a common trigger.